Clinical trials
Completed Infections trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ViiV Healthcare | 15 |
| European Organisation for Research and Treatment of Cancer - EORTC | 5 |
| GlaxoSmithKline | 2 |
| Istituto Ortopedico Rizzoli | 2 |
| University of Bologna | 2 |
| University of Turin, Italy | 2 |
| Abbott | 1 |
| Azienda Ospedaliera Universitaria Policlinico "G. Martino" | 1 |
| Aziende Chimiche Riunite Angelini Francesco S.p.A | 1 |
| Bionor Immuno AS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Infections | 52 |
| HIV Infections | 13 |
| Acquired Immunodeficiency Syndrome | 12 |
| Blast Crisis | 3 |
| Breast Neoplasms | 3 |
| Burkitt Lymphoma | 3 |
| COVID-19 | 3 |
| Hodgkin Disease | 3 |
| Immunoblastic Lymphadenopathy | 3 |
| Immunoglobulin Light-chain Amyloidosis | 3 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.